Inhibition of PD-L1/PD-1 Checkpoint Increases NK Cell-Mediated Killing of Melanoma Cells in the Presence of Interferon-Beta
Cancers · 05.12.2025 · 17 (24) · 3899
DOI: 10.3390/cancers17243899 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 05.12.2025. Verfasst von Anna Makowska und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, 52074 Aachen, Germany. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft (DFG, German Research Foundation).
Abstract (Originalsprache)
Background/Objectives: Melanoma is a highly malignant skin tumor with poor response to conventional chemotherapeutic regimens. Melanoma cells induce cytotoxic T cell-mediated immune responses, and immunotherapy has significantly improved survival rates for patients with advanced disease.
Methods
Here, we investigate NK cell-mediated melanoma cell killing and its regulation by PD-L1/PD-1 blockade and IFNβ. Four melanoma cell lines were used in this study. To evaluate NK cell cytotoxicity, cells were exposed to NK cells with or without IFNβ. The calcein release assay was used to measure cell death, while specific inhibitors and siRNA silencing were applied to determine the contribution of individual effector pathways.
Results
NK cells were able to kill melanoma cells with sensitivity to killing varying between different cell lines. Cytotoxic effects were mainly mediated through activation of the TRAIL signaling cascade. In cell lines with low sensitivity to NK cell killing, expression of PD-L1 was noted and killing by NK cells could be significantly increased by inhibition of the PD-L1/PD-1 checkpoint. Killing of melanoma cells could be further increased by incubation of NK cells with IFNβ.
Conclusions
Our results point to a role of NK cells in the killing of melanoma cells and a potential clinical benefit of a combination therapy of IFNβ and anti-PD-1 antibody.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, 52074 Aachen, Germany.
- Department of Dermatology and Allergology, University Hospital RWTH Aachen, Pauwelsstraße 30, 52074 Aachen, Germany.
- Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), 52074 Aachen, Germany.
ORCID-Profile: Anna Makowska, Udo Kontny
Förderung
- Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)
Zitieren
APA
Makowska, A., Shen, L., Nothbaum, C., Panayotova-Dimitrova, D., Feoktistova, M., Yazdi, A. S., & Kontny, U. (2025). Inhibition of PD-L1/PD-1 Checkpoint Increases NK Cell-Mediated Killing of Melanoma Cells in the Presence of Interferon-Beta. Cancers, 17(24), 3899. https://doi.org/10.3390/cancers17243899
Vancouver
Makowska A, Shen L, Nothbaum C, Panayotova-Dimitrova D, Feoktistova M, Yazdi AS, et al. Inhibition of PD-L1/PD-1 Checkpoint Increases NK Cell-Mediated Killing of Melanoma Cells in the Presence of Interferon-Beta. Cancers. 2025;17(24):3899. doi:10.3390/cancers17243899
BibTeX
@article{Makowska2025,
author = {Makowska, Anna and Shen, Lian and Nothbaum, Christina and Panayotova-Dimitrova, Diana and Feoktistova, Maria and Yazdi, Amir S and Kontny, Udo},
title = {Inhibition of PD-L1/PD-1 Checkpoint Increases NK Cell-Mediated Killing of Melanoma Cells in the Presence of Interferon-Beta},
journal = {Cancers},
year = {2025},
volume = {17},
number = {24},
pages = {3899},
doi = {10.3390/cancers17243899}
}
EUVIMED